Amphotericin B not the only cure available for black fungus: ICMR
The Indian Council of Medical Research (ICMR) told the court that other amphotericin formulations are also available and can be used with supplementary medicines to reduce toxic effects
BusinessToday.In | June 4, 2021 | Updated 15:53 IST
A doctor checks the eyes of a patient who is suffering from mucormycosis also non as black fungus (Reuters photo)
The Indian Council of Medical Research (ICMR) informed the Delhi High Court on Friday that Liposomal Amphotericin B is not the only medication available for the treatment of mucormycosis, also called black fungus.
ICMR said it while submitting a policy on the distribution of the said drug for treating black fungus.
New Delhi [India], June 4 (ANI): The Indian Council of Medical Research (ICMR) on Friday told the Delhi High Court that the issues pertaining to mucormycosis management and treatment were extensively examined in the meeting held along with the National Task Force (NTF) on COVID-19 on June 2.
The Delhi High Court on Tuesday asked the Centre to frame the policy on the distribution of the Liposomal Amphotericin B, a drug used in the treatment of black fungus.
The company said it was able to develop the emulsion-based formulation for the drug in-house in just three weeks and has a capacity to manufacture 10,000 vials per day, which will be enough to cater to nearly 6,000 patients per month.